Publications by authors named "Jean Marc Ferrero"

Claim this Profile
R
Rethinking EPO: A Paradigm Shift in Oncology?
Jean-Marc Ferrero, Baharia Mograbi, Rym Bouriga, Jocelyn Gal, Gérard Milano

Cancers (Basel)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03.
Olivier Trédan, Delphine Loirat, Sylvie Chabaud, Philippe Toussaint, Thierry Petit, Jean Marc Ferrero

Breast· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PROTACs and Glues: Striking Perspectives for Engineering Cancer Therapy À La Carte.
Jean-Marc Ferrero, Jocelyn Gal, Baharia Mograbi, Gérard Milano

Pharmaceuticals (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.
Etienne Brain, Olivier Mir, Emmanuelle Bourbouloux, Olivier Rigal, Jean-Marc Ferrero

Lancet· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De-Escalating Anticancer Treatment: Watch Your Step.
Jean-Marc Ferrero, Rym Bouriga, Jocelyn Gal, Gérard Milano

Cancers (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EMOTION: Assessing the Impact of a Telephone Intervention for Patients With Breast Cancer, a Randomized Controlled Trial.
Sara Contu, Christophe Hebert, Jean-Marc Ferrero, Anne Creisson, Véronique Mari

JCO Oncol Pract· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials.
Shanna Rajpar, Tony Ibrahim, Alexandra Carmel, Zahira Merabet, Philippe Vielh, Jean-Marc Ferrero

Eur Urol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporal evolution of breast cancer brain metastases treatments and outcomes.
Michele Bottosso, Gaia Griguolo, Severine Guiu, Maria Cristina Guarascio, Caroline Bailleux, Jean-Marc Ferrero

NPJ Breast Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyberneo trial investigating the efficacy of stereotactic radiotherapy combined to neoadjuvant chemotherapy for locally advanced breast cancer: 14-years follow-up results.
Syrine Ben Dhia, Renaud Schiappa, Jocelyn Gal, Jean-Marc Ferrero, Philippe Bahadoran

Cancer Radiother· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Regard to Bondiau et al.
Syrine Ben Dhia, Reneaud Schiappa, Joyclin Gal, Jean Marc Ferrero, Philippe Bahadoran

Int J Radiat Oncol Biol Phys· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Nicolas Roussot, Guillaume Constantin, Isabelle Desmoulins, Anthony Bergeron, Laurent Arnould, Jean-Marc Ferrero

Eur J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.
Emmanuel Chamorey, Marc Pujalte-Martin, Jean-Marc Ferrero, Hakim Mahammedi, Gwenaelle Gravis

Int J Mol Sci· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.
François-Clément Bidard, Nicolas Kiavue, William Jacot, Thomas Bachelot, Sylvain Dureau, Jean-Marc Ferrero

J Clin Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Jean-Marc Ferrero

Nat Commun· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Jean-Marc Ferrero

Nat Commun· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer.
Rayan Kabirian, Maria Alice Franzoi, Julie Havas, Charles Coutant, Olivier Tredan, Jean-Marc Ferrero

JAMA Netw Open· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.
Valentina Orlando, Damien Drubay, Pernelle Lavaud, Laura Faivre, François Lesaunier, Jean-Marc Ferrero

Clin Genitourin Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Fanny Le Du, Matthieu Carton, Thomas Bachelot, Mahasti Saghatchian, Barbara Pistilli, Jean Marc Ferrero

Oncologist· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival analysis of patient groups defined by unsupervised machine learning clustering methods based on patient metabolomic data.
Caroline Bailleux, David Chardin, Jean-Marie Guigonis, Jean-Marc Ferrero, Yann Chateau

Comput Struct Biotechnol J· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
Thomas Grinda, Alison Antoine, William Jacot, Paul-Henri Cottu, Thibault de la Motte Rouge, Jean-Marc Ferrero

Eur J Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of RUBY for Breast Cancer Knowledge Extraction From a Large French Electronic Medical Record System.
Renaud Schiappa, Sara Contu, Dorian Culie, Yann Chateau, Jocelyn Gal, Jean-Marc Ferrero

JCO Clin Cancer Inform· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis.
Grazia Arpino, Juan de la Haba Rodríguez, Jean-Marc Ferrero, Sabino De Placido, C Kent Osborne

Clin Cancer Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolomic Signatures of Scarff-Bloom-Richardson (SBR) Grade in Non-Metastatic Breast Cancer.
Caroline Bailleux, David Chardin, Jocelyn Gal, Jean-Marie Guigonis, Sabine Lindenthal, Jean-Marc Ferrero

Cancers (Basel)· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study.
Hélène François-Martin, Audrey Lardy-Cléaud, Barbara Pistilli, Christelle Levy, Véronique Diéras, Jean-Marc Ferrero

Cancers (Basel)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer.
Jean-Marc Ferrero, Hakim Mahammedi, Gwenaelle Gravis, Guilhem Roubaud, Philippe Beuzeboc

Pharmaceutics· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis